Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

Translating Practice into Research Program RFA

Submitted by Anonymous (not verified) on

This year the OSCTR is starting a research training program.

Translating Practice into Research (TPIR), for healthcare professionals, clinical investigators, and basic scientists funded by the NIH Oklahoma Shared Clinical and Translational Resources grant. The goal of the TPIR trainee program is to produce a group of clinicians and scientists who have the ability to translate their clinical observations and ideas for improving practice into practical and feasible research projects. Attached is a detailed description. 

Presbyterian Health Foundation Seed and Bridge Grants

Submitted by Anonymous (not verified) on

Presbyterian Health Foundation has graciously agreed to provide significant funds for seed and bridge grants for OUHC faculty members. 

ELIGIBILITY: Limited to OUHC faculty

DEADLINE: June 27, 2014 with an anticipated start date of October 1, 2014. 

Details about the program scope, submission process, eligibility, application guidelines and funding information are found in the attached announcements.

Seed grants

Subscribe to News

Recent Publications

Experimental induction of anti-muscarinic type-3-receptor extracellular loop antibodies by immunization with 4-hydroxy-2-nonenal modified Ro60 and unmodified Ro60

Clin Exp Immunol. 2025 Jan 21;219(1):uxae114. doi: 10.1093/cei/uxae114.

ABSTRACT

OBJECTIVE: Sjögren's Disease (SjD) subjects have decreased lacrimal/salivary gland function. Studies have proposed that autoantibodies targeting G-protein-coupled muscarinic acetylcholine-type-3-receptor (M3R) are potential clinical markers for SjD. We hypothesized that rabbits/mice immunized with 4-hydroxy-2-nonenal (HNE)-modified/unmodified Ro60 will develop an autoimmunity, specifically a SjD phenotype, thus expressing increased levels of anti-M3R antibodies.

Impact of COVID-19 Diagnosis on Weight Trajectories of Children in the US National COVID Cohort Collaborative

medRxiv [Preprint]. 2025 Jan 5:2025.01.03.25319927. doi: 10.1101/2025.01.03.25319927.

ABSTRACT

BACKGROUND: The COVID-19 pandemic has exacerbated the obesity epidemic, with both adults and children demonstrating rapid weight gain during the pandemic. However, the impact of having a COVID-19 diagnosis on this trend is not known.

Upcoming Events

Media

Copyright © 2026 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies